Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Movement Disorders

Fleqsuvy™ (baclofen) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Fleqsuvy™ (baclofen) oral suspension

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Medication Name

Approval Date

Category

Description

Fleqsuvy™ (baclofen) oral suspension

Jun 2023

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Note: First-Time Generic

Fleqsuvy™ (baclofen) oral suspension

Feb 2022

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle